Therefore, since OIS is one of the earliest tumor suppressor mechanisms that is triggered in response to activation of the MEK–ERK pathway by oncogenic mutations in KRAS or BRAF, founder cells have to first overcome OIS for tumor initiation to occur [85, 89, 90]. The gene discussed is BRAF; the disease is neoplasm.